Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Thomas L. Hunt"'
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class. It is approved in the USA to treat adults with acute bacterial skin and skin-structure infections and community-acquired bacterial pneumo
Autor:
Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas L. Hunt, Nicholas S. Hill
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 10 (2020)
Pulmonary Circulation, Vol 10 (2020)
A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation adm
Autor:
Thomas L. Hunt, LuAnn Bundrant, Alan Wilson, Kenneth Kassler-Taub, Chris Warner, Phil Banks, Praveen Tyle, Suma Gopinathan, Suman Wason, Kristi A. Boehm
Publikováno v:
Clinical therapeutics. 43(6)
Purpose For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a new small-molecule AP2-associated
Publikováno v:
Clinical Pharmacology in Drug Development
This study evaluated the effects of eluxadoline, a mixed μ‐opioid receptor (OR) and κ‐OR agonist and δ‐OR antagonist, on cardiac repolarization. This evaluator‐blinded, placebo‐ and positive‐controlled, 4‐period crossover study rando
Autor:
Hiroyuki Yamada, Sudhakar M. Pai, Tsutomu Shibata, Thomas L. Hunt, Sekihiro Tamaki, Barbara Gerhardt
Publikováno v:
Clinical pharmacology in drug development. 8(3)
Pharmacokinetics, safety, and tolerability of JTK-853, a novel HCV polymerase inhibitor, were evaluated in single and multiple ascending dose (SAD, MAD) studies, with food- and ketoconazole-related effects on exposure to JTK-853 and its active (CYP3A
Publikováno v:
The Journal of Clinical Pharmacology. 54:1221-1229
Prolongation of the QT interval has been observed with ondansetron and other members of the 5-HT3 antagonist class. This is the first thorough QTc study of ondansetron conducted in accordance with ICH E14 guidelines, designed to investigate the effec
Autor:
Thomas L. Hunt, Bharath Kumar, Mary E. Hanson, David L. Cutler, Fengjuan Xuan, Teddy Kosoglou, Paul Statkevich
Publikováno v:
Clinical Pharmacology in Drug Development. 3:18-24
In a randomized, double-blind (vorapaxar and placebo), placebo- and positive-controlled (moxifloxacin 400 mg) parallel group study, the effect of single-dose vorapaxar 120 mg on QT/QTc interval was assessed in 120 adults 18-50 years. Twelve-lead digi
Autor:
Thomas L Hunt, Christine Y. Yu, Craig A. Sponseller, Baojin Zhu, David S. Small, Mary Pat Knadler, Stuart E. Campbell, Roger E. Morgan
Publikováno v:
Current Medical Research and Opinion. 28:187-194
Statins have been shown to impact international normalized ratio (INR) when coadministered with warfarin. The aim of this study was to assess the effect of pitavastatin compared with rosuvastatin on steady-state pharmacodynamics (PD) of warfarin by m
Autor:
Daniel Neddermann, Thomas L. Hunt, Steve Maton, Robert Schmouder, Gilles-Jacques Riviere, John M. Kovarik
Publikováno v:
The Journal of Clinical Pharmacology. 48:303-310
The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) elicits a negative chronotropic effect at treatment initiation that attenuates thereafter. The authors determined whether isoproterenol can counteract this effect. In this randomized,
Publikováno v:
Future microbiology. 10(11)
Aims: AFN–1252 is a novel inhibitor of FabI, an essential enzyme in Staphylococcus spp. This study was undertaken to assess the safety, tolerability and pharmacokinetic properties of AFN–1252, following oral administration in an ascending dose tr